Armune BioScience Secures Contract for Apifiny with America's Choice Provider Network to Expand Access to Apifiny

Share Article

Apifiny test to be covered by over 1,700 ACPN payers in North America covering over 22 million lives.

Armune BioScience Logo
Securing a contract with ACPN is another example of the potential game-changing clinical and economic value that Apifiny offers.

Armune BioScience, an emerging leader in break-through cancer diagnostics, has secured a contractual agreement for Apifiny with America’s Choice Provider Network (ACPN), a leading preferred provider organization (PPO). Under the terms of the agreement, Armune is established as a preferred provider, and its Apifiny test will be covered by over 1,700 payers in North America covering over 22 million lives. Armune continues to expand patient access to Apifiny through a growing number of insurance providers and reference laboratories.

Launched in the United States in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to help move beyond PSA based testing to assess prostate cancer risk.

“We are very much looking forward to having an innovative provider such as Armune BioScience in our national provider network. Contracting with providers such as Armune BioScience ensures that our members have access to the best care,” said Seth Breeden, chief operating officer of ACPN. “It is with great excitement that we can now offer our members access to Apifiny to help in the detection of prostate cancer detection.”

“Securing a contract with ACPN is another example of the potential game-changing clinical and economic value that Apifiny offers,” said David A. Esposito, President and CEO of Armune BioScience. “Given the current concerns of PSA testing throughout the world, Apifiny is well positioned to offer clinicians additional information in the assessment of prostate cancer risk. In addition, we are confident that Apifiny will help to address our healthcare system’s demand for improved outcomes at lower costs.”

Apifiny was developed based on innovative research into the immune system’s response to cancer conducted at the University of Michigan. Armune is currently expanding testing throughout the United States and preparing to launch Apifiny in several markets worldwide. Armune recently retained Mavericks Capital as the Company’s advisor and investment bank.

About America’s Choice Provider Network (
Founded in 2012, ACPN is an independent, multispecialty national provider network. Through its proprietary network and technology, ACPN offers access to providers, payers and patients in all 50 States, Canada, the Dominican Republic, Guam, Mexico, and Puerto Rico. ACPN’s products include Individual and Group Health, Workers Compensation, Auto Liability, and Medicare Advantage. Its client base consists of Insurance Carriers, Third Party Administrators, Health and Welfare Funds, Self-Administered Employer Groups, Student Plans, Travel Plans, etc. ACPN’s mission is to achieve consistency in healthcare transactions, simplify claims adjudication processes, create reasonable reimbursement arrangements, and establish reliable healthcare access for all parties—providers, payers and patients.

About Mavericks Capital (
Mavericks Capital LLC and its licensed broker dealer, Mavericks Capital Securities LLC, specializes in advising companies on M&A, capital raises and strategic partnerships across the healthcare sector. With a senior team having deep medical perspectives, core scientific knowledge and proprietary analytics, we help construct and facilitate innovative and lucrative solutions for our clients. Our practice areas include therapeutics, devices, diagnostics, services and digital health.

About Armune BioScience (
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sue Crookston
Follow >
Follow us on
Visit website